$34.01
Value $98M
KEQU and RTX stock compared: price, dividend, valuation and results, from SEC filings.
$34.01
Value $98M
$198.00
Value $266B
Kewaunee Scientific (KEQU) has a market value of $98M and RTX (RTX) $266B. Over the last year, with dividends, KEQU moved -15.9% and RTX +14.4%. The P/E is 11.9 for KEQU and 31.6 for RTX. Dividend yield: KEQU none, RTX 1.42%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
KEQU$98M
RTX$266B
RTX is 2,721 times KEQU
Revenue, 12 months
KEQU$277M
RTX$96.0B
RTX is 346 times KEQU
Net income, 12 months
KEQU$8.2M
RTX$8.4B
RTX is 1,021 times KEQU
Operating margin
KEQU5.4%
RTX11.8%
6.4 points apart
ROIC
KEQU11.4%
RTX8.8%
2.6 points apart
P/E
KEQU11.9
RTX31.6
RTX is 2.7 times KEQU
Dividend yield
KEQU0.0%
RTX1.4%
1.4 points apart
5-year return
KEQU+167.2%
RTX+148.0%
19.2 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
KEQU+167.2%
RTX+148.0%
| Period | KEQUWith dividends | RTXWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | -15.9%Price -15.9% | +14.4%Price +12.8% |
| 3 years since November 17, 2023 | +84.2%+22.6% a yearPrice +84.2% | +161.9%+37.8% a yearPrice +148.5% |
| 5 years since November 16, 2021 | +167.2%+21.7% a yearPrice +167.2% | +148.0%+19.9% a yearPrice +122.7% |
| 10 years since November 17, 2016 | +62.7%+5.0% a yearPrice +49.6% | +268.0%+13.9% a yearPrice +194.9% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
KEQUKewaunee ScientificRTXRTX
| Price | $34.01 | $198.00 |
|---|---|---|
| Market value | $98M | $266B |
| Enterprise value (EV) | – | $293B |
| P/E | 11.9 | 31.6 |
| P/E, 5-year median | 9.9 | 33.6 |
| P/B | 1.3 | 3.8 |
| EV/EBIT | – | 25.9 |
| Free cash flow yield | 11.1% | 3.6% |
| Revenue, 12 months | $277M | $96.0B |
|---|---|---|
| Net income, 12 months | $8.2M | $8.4B |
| Free cash flow, 12 months | $11M | $9.5B |
| Earnings per share, 12 months | $2.76 | $6.16 |
| Revenue growth, year on year | 17.3% | 9.7% |
| Revenue growth a year, past | +13.8%over 5 years | +9.4%over 5 years |
| EPS growth a year, past | – | – |
| Gross margin | 28.5% | – |
|---|---|---|
| Operating margin | 5.4% | 11.8% |
| Net margin | 3.0% | 8.8% |
| ROIC | 11.4% | 8.8% |
| ROE | 11.5% | 12.7% |
| Cash | $8.2M | $9.9B |
|---|---|---|
| Total debt | – | $38.9B |
| Net debt / EBITDA | – | 1.8 |
| Interest cover | 3.5× | – |
| Dividend yield | – | 1.4% |
|---|---|---|
| Dividend per share, 12 months | – | $2.82 |
| Dividend growth a year, past | – | +4.3%over 5 years |
| Buyback yield | – | 0.0% |
| Shareholder yield | – | 1.4% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, RTX ($266B) is about 2,720.7 times Kewaunee Scientific ($98M), at today's prices.
Since November 17, 2016, KEQU's price moved +49.6% and RTX's +194.9%. With dividends: KEQU +62.7% (+5.0% a year), RTX +268.0% (+13.9% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Kewaunee Scientific and 1.42% for RTX. Over the last twelve months they paid – and $2.82 per share.
At today's price, the P/E is 11.9 for KEQU and 31.6 for RTX. The median of the last five years was 9.9 and 33.6, which shows where each stands against its own past.
Over the last twelve months, the net margin was 3.0% for Kewaunee Scientific and 8.8% for RTX, and the operating margin 5.4% and 11.8%. Revenue was $277M and $96.0B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.